
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health is facing some headwinds in the autoimmune and chronic inflammatory therapy segment, but management is taking steps to improve leverage and optimize procurement activities. The company's capital allocation priorities prioritize internal investment and M&A, which aligns with previous management commentary. Although there are some concerns about the first quarter earnings report and guidance, Option Care is well-positioned in the home and alternate-site infusion market and has historically exceeded financial guidance. The company's improved margins and momentum in acute therapies are also positive indicators.
Bears say
Option Care Health is facing headwinds in its chronic therapies revenue, as well as a negative cash flow from operations, leading to substantial capital expenditures. They have a history of overpromising and underdelivering, leading to negative reactions from shareholders. Additionally, the portfolio is de-risked, but it remains uncertain if the company can resume its previous track record of margin expansion. This, combined with the negative cash flow and reliance on a single drug, makes Option Care Health's stock risky for investors.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares